Johnson & Johnson (JNJ): FY25 Q2 earnings call, Jul 16, 2025
No Kalshi or Polymarket word markets were listed for Johnson & Johnson’s Jul 16, 2025 earnings call (FY25 Q2). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
5 matches for “Caplyta”; 3 quoted, at least 25 words apart.
…depression. We also completed the acquisition of intracellular therapies this quarter. Intracellular CAPLYTA is approved to treat adults with schizophrenia and bipolar depression and we…
…lung cancer in the U.S. TREMFYA subcutaneous induction for ulcerative colitis and CAPLYTA for adjunctive major depressive disorder. Anticipated filings for approval include icotracindra in…
…ulcerative colitis and also Crohn's disease and across neuroscience, both [indiscernible] and CAPLYTA had really, really strong performance for the quarter. So as I mentioned,…
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2025-07-16:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2025-07-16:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP